News und Analysen
![Chemed To Report Third-Quarter 2020 Earnings October 29, Related Conference Call To Be Held On October 30](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
Chemed To Report Third-Quarter 2020 Earnings October 29, Related Conference Call To Be Held On October 30
Chemed Corporation (NYSE:CHE) today announced that it will release financial results for the third quarter ended September 30, 2020, on Thursday, October 29, 2020, following the close of trading on
![LivaNova Presents New Data at European Association for Cardio-Thoracic Surgery Annual Meeting Demonstrating Benefits of Perceval Sutureless Valve: https://mms.businesswire.com/media/20191101005329/en/555341/5/LN-Logo-Main-PANTONE.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBN01qRUE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--21a914cdc6fc0b7ffdd18c2667f61a9a3ee0c178/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/LN-Logo-Main-PANTONE.jpg?locale=de)
LivaNova Presents New Data at European Association for Cardio-Thoracic Surgery Annual Meeting Demonstrating Benefits of Perceval Sutureless Valve
LivaNova PLC (NASDAQ:LIVN) a market-leading medical technology and innovation company, today announced new data from the Perceval® Sutureless Implant Versus Standard-Aortic Valve Replacement
![CORRECTING and REPLACING PerkinElmer Updates Third Quarter Outlook; To Hold Earnings Call on Wednesday, October 28, 2020](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
CORRECTING and REPLACING PerkinElmer Updates Third Quarter Outlook; To Hold Earnings Call on Wednesday, October 28, 2020
The table in the release was incorrect. The corrected table should read:
PerkinElmer, Inc:
PerkinElmer, Inc. and SubsidiariesRECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES (1)
![Roche Selects Veeva Development Cloud Applications](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
Roche Selects Veeva Development Cloud Applications
Veeva Systems (NYSE: VEEV) today announced that Roche (SWX: ROG) has selected Veeva Development Cloud applications globally to streamline clinical, regulatory, and quality processes. The company is
![Leading Companies Accelerating Clinical Trials With Veeva Vault CDMS](/assets/news/news4-fce0efe65d8ba787508ef718c0a20bed51e468dbc656c188c43e13f15b4a4f53.png)
Leading Companies Accelerating Clinical Trials With Veeva Vault CDMS
Veeva Systems (NYSE: VEEV) today announced that an increasing number of companies are adopting Veeva Vault CDMS to manage their clinical data. More emerging biotechs and global organizations
![More Than 300 Companies Adopt Vault Quality Applications to Unify Global Quality Processes](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
More Than 300 Companies Adopt Vault Quality Applications to Unify Global Quality Processes
Veeva Systems (NYSE: VEEV) today announced increasing numbers of biopharma, contract services, generics, and medical device and diagnostics companies are adopting Veeva Vault Quality Suite
![Selecta Biosciences: NBC sagt Byebye nach +60% in einer Woche](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
Selecta Biosciences: NBC sagt Byebye nach +60% in einer Woche
Zu Monatsbeginn konnten Mitglieder des No Brainer Clubs mit der Aktie von Selecta Biosciences (WKN: A2AML0) ein weiteres Schnäppchen ergattern. Nach vermeintlich enttäuschenden Studiendaten rutschte
![Navidea Biopharmaceuticals Announces Acceptance of Abstract for Presentation at the American College of Rheumatology Annual Meeting: https://mms.businesswire.com/media/20191107006076/en/389794/5/navidea_cmyk.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNllsRUE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--8f98c3cfd17bc93aed823f932a665c78f3f036eb/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/navidea_cmyk.jpg?locale=de)
Navidea Biopharmaceuticals Announces Acceptance of Abstract for Presentation at the American College of Rheumatology Annual Meeting
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today
![PENELOPE-B Trial of IBRANCE® (palbociclib) in Early Breast Cancer Did Not Meet Primary Endpointhttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBZHc9IiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--be1a2af5756eaa0acf5414ead3504a7e3ad45f8a/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Pfizer.jpg?locale=de)
PENELOPE-B Trial of IBRANCE® (palbociclib) in Early Breast Cancer Did Not Meet Primary Endpoint
The German Breast Group (GBG) and Pfizer Inc. (NYSE: PFE) today announced that the collaborative Phase 3 PENELOPE-B trial did not meet the primary endpoint of improved invasive disease-free
![No Brainer Club: Ex-Empfehlung mit +2.409% in 7 Monaten](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
No Brainer Club: Ex-Empfehlung mit +2.409% in 7 Monaten
Cardiff Oncology (WKN: A2P4GU) ist einer der diesjährigen Überflieger an der Nasdaq. Seit ihrem Jahrestief bei 0,70 USD steht für die Aktie eine gigantische Performance von +2.409% in nur sieben
![NeutriSci Partner Tabletz LLC launcht Website und Social-Media-Plattformen zur Eroberung des japanischen CBD-Marktes](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
NeutriSci Partner Tabletz LLC launcht Website und Social-Media-Plattformen zur Eroberung des japanischen CBD-Marktes
VANCOUVER, BC / 8. Oktober 2020 / NeutriSci International Inc. („NeutriSci“ oder das „Unternehmen“) (TSX-V:NU)(OTCQB:NRXCF)(FRANKFURT:1N9) - ein innovatives Technologieunternehmen, welches
![Neutrisci Partner Tabletz LLC Launches Website and Social Media Platforms to Conquer Japanese CBD Market](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
Neutrisci Partner Tabletz LLC Launches Website and Social Media Platforms to Conquer Japanese CBD Market
VANCOUVER, BC / October 8, 2020 / NeutriSci International Inc. ("NeutriSci" or the "Company") (TSX-V:NU, OTCQB:NRXCF, FRANKFURT:1N9), an innovative technology company developing products for
![AMN Healthcare to Host Third Quarter 2020 Earnings Conference Call on Thursday, November 5, 2020](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
AMN Healthcare to Host Third Quarter 2020 Earnings Conference Call on Thursday, November 5, 2020
AMN Healthcare Services, Inc. (NYSE: AMN), the leader and innovator in total talent solutions for healthcare organizations, has scheduled a conference call to discuss its third quarter 2020
![MEDICREA Reports Third Quarter 2020 Sales](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
MEDICREA Reports Third Quarter 2020 Sales
The MEDICREA® Group (Euronext Growth Paris: FR0004178572 – ALMED ; OTCQX Best Market –MRNTF), pioneering the transformation of spinal surgery through Artificial Intelligence, predictive modeling
![Agilent Announces the Availability of Objective Decision Support for Pathologists Reviewing Breast Cancer Cases](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
Agilent Announces the Availability of Objective Decision Support for Pathologists Reviewing Breast Cancer Cases
Agilent Technologies Inc. (NYSE: A) today announced the expansion of Visiopharm’s validated image analysis algorithm to incorporate HercepTest™ mAb pharmDx for Dako Omnis, both CE-IVD marked and
![Humana Expanding in New Jersey, Will Sell Medicare Advantage Plans in Four More Counties: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24514/Humana_logo.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBaXNCIiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--3d3c39355769d1759c5221ae0bf511106538ecb5/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Humana_logo.png?locale=de)
Humana Expanding in New Jersey, Will Sell Medicare Advantage Plans in Four More Counties
Leading health and well-being company Humana Inc. (NYSE: HUM) announced today it will grow its New Jersey market footprint by offering Medicare Advantage plans in four additional counties in the
![Lantheus Holdings Announces Presentations at the 33rd Annual European Association of Nuclear Medicine (EANM) Virtual Congress](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
Lantheus Holdings Announces Presentations at the 33rd Annual European Association of Nuclear Medicine (EANM) Virtual Congress
Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc., Progenics Pharmaceuticals, Inc., and EXINI Diagnostics AB, and a global leader in the
![IMV Provides Updates On COVID-19 Vaccine Program: https://mms.businesswire.com/media/20200225005324/en/775456/5/IMV_Logos_IMV-Logo_BrandStatement.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBenlNSlE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--44b7c2e9ec1d34b6817ce17f4c733565e4a558a7/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/IMV_Logos_IMV-Logo_BrandStatement.jpg?locale=de)
IMV Provides Updates On COVID-19 Vaccine Program
IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious diseases, today provides updates on
![Pfizer Announces Positive Phase 3 Top-line Results for Once-Weekly Investigational Long-Acting Human Growth Hormone to Treat Children with Growth Hormone Deficiencyhttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBZHc9IiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--be1a2af5756eaa0acf5414ead3504a7e3ad45f8a/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Pfizer.jpg?locale=de)
Pfizer Announces Positive Phase 3 Top-line Results for Once-Weekly Investigational Long-Acting Human Growth Hormone to Treat Children with Growth Hormone Deficiency
Pfizer Inc. (NYSE: PFE) and OPKO Health Inc. (NASDAQ: OPK) announced today that C0311002, a Phase 3, randomized, multicenter, open-label, crossover study evaluating somatrogon dosed once-weekly in
![CO.DON AG: Erfolgreicher Abschluss der Kapitalerhöhung](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
CO.DON AG: Erfolgreicher Abschluss der Kapitalerhöhung
- vollständige Platzierung aller angebotenen Aktien
- Bruttoemissionserlös in Höhe von rund 1,5 Mio. EUR
Berlin / Teltow / Leipzig, 08. Oktober 2020 – Die CO.DON AG (ISIN
![NanoString Technologies Announces Pricing of Upsized Public Offering of $200 Million of Common Stock: https://mms.businesswire.com/media/20191104005218/en/753909/5/NSTG-Logo-19-%28002%29.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBLzhpRUE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--b6ef578a6eaa604de21c95a83c7b989a1a3263c9/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/NSTG-Logo-19--28002-29.jpg?locale=de)
NanoString Technologies Announces Pricing of Upsized Public Offering of $200 Million of Common Stock
NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced the pricing of an upsized underwritten public
![Hanger Announces Date of 2020 Third Quarter Earnings Release and Conference Call](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
Hanger Announces Date of 2020 Third Quarter Earnings Release and Conference Call
Hanger, Inc. (NYSE: HNGR), a leading provider of orthotic and prosthetic patient care services and solutions, today announced it will report its financial results for the third quarter and nine
![New Veeva Clinical Network Applications Connect Sponsors, Sites, and Patients to Accelerate Clinical Trials](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
New Veeva Clinical Network Applications Connect Sponsors, Sites, and Patients to Accelerate Clinical Trials
Veeva Systems (NYSE: VEEV) today announced the first two applications built on the Veeva Clinical Network, the industry’s only solution that links sponsors, clinical research sites, and patients
![Alexion Pharma: Völlig egal, ob der Mega-Merger kommt!](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
Alexion Pharma: Völlig egal, ob der Mega-Merger kommt!
Zu den Topgewinnern an den US-Aktienmärkten zählt heute die Aktie des Biopharmakonzerns Alexion Pharmaceutical (WKN: 899527). Da stellt sich natürlich die Frage nach dem Warum?
Schließlich
![Humana Medicare Advantage Members Benefit From Improved Health Outcomes, Preventive Care and an Estimated $4 Billion in Reduced Costs Through Value-Based Care : http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24514/Humana_logo.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBaXNCIiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--3d3c39355769d1759c5221ae0bf511106538ecb5/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Humana_logo.png?locale=de)
Humana Medicare Advantage Members Benefit From Improved Health Outcomes, Preventive Care and an Estimated $4 Billion in Reduced Costs Through Value-Based Care
Humana Inc. (NYSE: HUM) unveiled today its annual Value-based Care Report, detailing that 2.41 million Humana individual Medicare Advantage beneficiaries receiving care from primary care physicians